NADAC acquisition cost data for AZOPT 1% EYE DROPS. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00065027510 | $34.63 | 2022-07-27 | Rx |
| 00078072210 | $34.63 | 2022-07-27 | Rx |
| 00065027515 | $34.72 | 2022-07-27 | Rx |
| 00065027510 | $34.63 | 2022-07-27 | Rx |
| 00078072210 | $34.63 | 2022-07-27 | Rx |
| 00065027515 | $34.72 | 2022-07-27 | Rx |
| 00065027510 | $34.63 | 2022-07-27 | Rx |
| 00078072210 | $34.63 | 2022-07-27 | Rx |
| 00065027515 | $34.72 | 2022-07-27 | Rx |
| 00065027510 | $34.63 | 2022-07-27 | Rx |
Generic: Brinzolamide | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | 101,287 | N/A |
| 2020 | N/A | N/A | 84,859 | N/A |
| 2021 | N/A | N/A | 59,040 | N/A |
| 2022 | $16.1M | 35,157 | 22,399 | $36.77 |
| 2023 | $21.8M | 45,061 | 12,393 | $37.20 |
These generic drugs may be equivalent alternatives at lower prices.
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $4.9M | 9,974 | 2,618 |
| New York | $2.7M | 5,334 | 1,407 |
| Puerto Rico | $2.2M | 5,902 | 1,529 |
| Florida | $1.3M | 2,673 | 719 |
| Texas | $987.3K | 2,082 | 678 |
| Pennsylvania | $805.3K | 1,539 | 446 |
| New Jersey | $757.3K | 1,369 | 411 |
| Massachusetts | $732.5K | 1,339 | 392 |
| Illinois | $671.1K | 1,252 | 390 |
| Georgia | $497.8K | 958 | 298 |
| North Carolina | $422.6K | 854 | 248 |
| Arizona | $420.7K | 843 | 262 |
| Ohio | $383.3K | 769 | 225 |
| Connecticut | $366.3K | 639 | 190 |
| Michigan | $324.5K | 608 | 202 |
| Virginia | $319.1K | 551 | 170 |
| Maryland | $307.3K | 573 | 208 |
| Missouri | $286.5K | 578 | 158 |
| Wisconsin | $258.7K | 583 | 146 |
| Indiana | $250.6K | 491 | 151 |
| South Carolina | $246.1K | 506 | 132 |
| Washington | $234.9K | 474 | 132 |
| Tennessee | $234.3K | 462 | 138 |
| Oregon | $195.2K | 433 | 126 |
| Mississippi | $170.8K | 406 | 107 |
| Louisiana | $167.7K | 365 | 114 |
| Iowa | $151.0K | 367 | 121 |
| Minnesota | $132.0K | 273 | 94 |
| Kansas | $129.6K | 303 | 72 |
| Oklahoma | $111.1K | 227 | 63 |
| Colorado | $110.8K | 205 | 66 |
| Kentucky | $102.5K | 205 | 78 |
| Alabama | $98.6K | 214 | 61 |
| Maine | $82.0K | 167 | 60 |
| New Hampshire | $79.1K | 155 | 52 |
| Nevada | $77.2K | 152 | 43 |
| Rhode Island | $72.7K | 133 | 34 |
| Arkansas | $58.9K | 132 | 40 |
| North Dakota | $57.9K | 146 | 42 |
| Utah | $50.4K | 96 | 34 |
| Nebraska | $47.6K | 96 | 34 |
| Montana | $39.5K | 71 | 19 |
| Vermont | $37.4K | 74 | 25 |
| Delaware | $37.2K | 74 | 26 |
| South Dakota | $32.2K | 68 | 20 |
| District of Columbia | $31.7K | 63 | 20 |
| Alaska | $27.0K | 45 | 15 |
| West Virginia | $26.9K | 61 | 24 |
| Hawaii | $24.9K | 35 | 11 |
| New Mexico | $21.9K | 47 | 14 |
| Idaho | $16.6K | 42 | 17 |
| Wyoming | $10.0K | 24 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.